Evidence map›Paper›PMID 25486199›Full record

ArticleCell cycle (Georgetown, Tex.)2014

Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.

Joseph A Caruso, Rody Campana, Caimiao Wei, Chun-Hui Su, Amanda M Hanks, William G Bornmann, Khandan Keyomarsi

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Nutrients · 2020
    Review
  12. Structure-Based Classification and Anti-Cancer Effects of Plant Metabolites.International journal of molecular sciences · 2018
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Joseph A Carusoa Department of Experimental Radiation Oncology ; University of Texas MD Anderson Cancer Center ; Houston , TX USA.
Rody Campana
Caimiao Wei
Chun-Hui Su
Amanda M Hanks
William G Bornmann
Khandan Keyomarsi
The University of Texas MD Anderson Cancer Center · USThe University of Texas at Austin · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Proteolytic Processing of Cyclin E in Breast CancerR01CA087548 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KEYOMARSI, KHANDAN · 2001 to 2015
$4.1M
Targeting the cell cycle in triple negative breast cancerR01CA152228 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KEYOMARSI, KHANDAN · 2011 to 2015
$2.3M
Multidisciplinary Subspecialty Pathology Research Fellowship ProgramT32CA163185 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CZERNIAK, BOGDAN A, KEYOMARSI, KHANDAN · 2011 to 2015
$1.7M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA087548NCI NIH HHS R01 CA152228NCI NIH HHS T32 CA163185
6 · The paper itself

Abstract

Indole-3-carbinol (I3C) is a natural anti-carcinogenic compound found at high concentrations in Brassica vegetables. I3C was recently reported to inhibit neutrophil elastase (NE) activity, while consequently limiting the proteolytic processing of full length cyclin E into pro-tumorigenic low molecular weight cyclin E (LMW-E). In this study, we hypothesized that inhibition of NE activity and resultant LMW-E generation is critical to the anti-tumor effects of I3C. LMW-E was predominately expressed by ERα-negative breast cancer cell lines. However, ERα-positive cell lines demonstrated the greatest sensitivity to the anti-tumor effects of I3C and its more potent N-alkoxy derivatives. We found that I3C was incapable of inhibiting NE activity or the generation of LMW-E. Therefore, this pathway did not contribute to the anti-tumor activity of I3C. Gene expression analyzes identified ligand-activated aryl hydrocarbon receptor (AhR), which mediated sensitivity to the anti-tumor effects of I3C in ERα-positive MCF-7 cells. In this model system, the reactive oxygen species (ROS)-induced upregulation of ATF-3 and pro-apoptotic BH3-only proteins (e.g. NOXA) contributed to the sensitivity of ERα-positive breast cancer cells to the anti-tumor effects of I3C. Overexpression of ERα in MDA-MB-231 cells, which normally lack ERα expression, increased sensitivity to the anti-tumor effects of I3C, demonstrating a direct role for ERα in mediating the sensitivity of breast cancer cell lines to I3C. Our results suggest that ERα signaling amplified the pro-apoptotic effect of I3C-induced AhR signaling in luminal breast cancer cell lines, which was mediated in part through oxidative stress induced upregulation of ATF-3 and downstream BH3-only proteins.

Indexed as

AlcoholsAntineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorCell ProliferationCyclin EEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansIndolesLeukocyte ElastaseMetabolic Networks and PathwaysReceptors, Aryl HydrocarbonSignal TransductionAlcoholsalkoxyl radicalAntineoplastic AgentsCyclin EESR1 protein, humanEstrogen Receptor alphaindole-3-carbinolIndolesLeukocyte ElastaseReceptors, Aryl HydrocarbonAhR, aryl hydrocarbon receptoraryl hydrocarbon receptorCYP, cytochrome p450 oxidasesDIM, 3,3-diindoylmethaneERα, estrogen receptor αestrogen receptor αHMECs, human mammary epithelial cellsI3C, indole-3-carbinolindole-3-carbinolLMW-E, low molecular weight cyclin ENE, neutrophil elastaseneutrophil elastaseROS, reactive oxygen speciesRPPA, reverse phase protein arrayTNBC, triple-receptor negative breast cancer

Identifiers

PMID25486199
PMCPMC4614451
OpenAlexW1983821021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.